Priority Review for Teva's mAb to treat migraine

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) said FDA accepted and granted Priority Review to a BLA for fremanezumab (TEV-48125) to prevent migraine.

Teva said it submitted a Priority Review voucher with the BLA, and expects regulatory action by mid-2018. Teva declined to disclose from whom it bought the voucher...